ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 758,53
0,05%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MEI Pharma Inc (MEIP)

  7. MEI Pharma Inc (MEIP) Actualités

MEIP

MEI Pharma (MEIP)

MEI Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MEIP
DateHeureSourceTitreSymboleSociété
21/05/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MEIPMEI Pharma Inc
21/05/202419h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
09/05/202422h02Business WireMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational HighlightsNASDAQ:MEIPMEI Pharma Inc
09/05/202422h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MEIPMEI Pharma Inc
11/04/202414h02Business WireMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344NASDAQ:MEIPMEI Pharma Inc
11/04/202414h00Business WireMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsNASDAQ:MEIPMEI Pharma Inc
10/04/202414h00Business WireMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:MEIPMEI Pharma Inc
26/03/202413h00Business WireMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaNASDAQ:MEIPMEI Pharma Inc
29/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MEIPMEI Pharma Inc
20/02/202423h33Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MEIPMEI Pharma Inc
13/02/202423h05Business WireMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsNASDAQ:MEIPMEI Pharma Inc
16/01/202423h00Business WireMEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024NASDAQ:MEIPMEI Pharma Inc
12/01/202422h00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:MEIPMEI Pharma Inc
11/12/202318h00Business WireMEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023NASDAQ:MEIPMEI Pharma Inc
15/11/202302h59Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MEIPMEI Pharma Inc
09/11/202322h05Business WireMEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational HighlightsNASDAQ:MEIPMEI Pharma Inc
08/11/202323h04Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:MEIPMEI Pharma Inc
08/11/202323h03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MEIPMEI Pharma Inc
08/11/202323h02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MEIPMEI Pharma Inc
08/11/202314h00Business WireMEI Pharma to Present at the Stifel 2023 Healthcare ConferenceNASDAQ:MEIPMEI Pharma Inc
06/11/202322h57Business WireMEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common StockNASDAQ:MEIPMEI Pharma Inc
02/11/202314h00Business WireMEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023NASDAQ:MEIPMEI Pharma Inc
01/11/202322h20Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MEIPMEI Pharma Inc
01/11/202322h15Edgar (US Regulatory)Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialNASDAQ:MEIPMEI Pharma Inc
01/11/202314h00Business WireMEI Pharma Enters into Agreement with Anson Funds and Cable Car CapitalNASDAQ:MEIPMEI Pharma Inc
27/10/202322h05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:MEIPMEI Pharma Inc
17/10/202323h33Business WireMEI Pharma Recommends Stockholders Not to ConsentNASDAQ:MEIPMEI Pharma Inc
17/10/202323h28Edgar (US Regulatory)Form DEFC14A - Definitive proxy statement, contested solicitationsNASDAQ:MEIPMEI Pharma Inc
12/10/202323h25Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:MEIPMEI Pharma Inc
03/10/202312h33Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:MEIPMEI Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:MEIP

Dernières Valeurs Consultées

TSX
GAU
Galiano Gold
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés